The verdict is even harsher for GlaxoSmithKline, which gets seven buy ratings, eight hold ratings and three sell tags from the analysts surveyed. Roche의 주가는 현재까지 상승했습니다. In comparison, Novartis has risen., while GlaxoSmithKline has shed.